BofA lowered the firm’s price target on Myriad Genetics (MYGN) to $11 from $13 and keeps an Underperform rating on the shares after Myriad ...

Analysts are pulling back from the Healthcare sector as 2 experts expressed today bearish sentiments on Myriad Genetics (MYGN – Research ...

Genetic testing company Myriad Genetics (NASDAQ:MYGN) in Q4 CY2024, but sales rose 7.1% year on year to $210.6 million. The ...

Q4 2024 Earnings Call Transcript February 24, 2025 Operator: Good day, and thank you for standing by. Welcome to the Myriad ...

UnitedHealthcare will stop covering Myriad Genetics' GeneSight test in 2025, impacting $45 million in revenue. Myriad ...

Myriad Genetics Chief Executive Paul J. Diaz will leave the company April 30 to return to private equity firm Cressey & Co., where he will be a managing partner. The former Kindred Healthcare CEO was ...

Appoints Sam Raha as CEO and Mark S. Verratti as COO Effective April 30, 2025SALT LAKE CITY, Feb. 24, 2025 (GLOBE NEWSWIRE) - ...

Equities research analysts at Leerink Partnrs reduced their Q1 2025 earnings estimates for shares of Myriad Genetics in a research report issued on Tuesday, February 25th. Leerink Partnrs analyst P.

New York State Common Retirement Fund boosted its position in shares of Myriad Genetics, Inc. (NASDAQ:MYGN – Free Report) by ...

Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics testing and precision medicine, today announced a ...

Good day, and thank you for standing by. Welcome to the Myriad Genetics Fourth Quarter 2024 Financial Earnings Conference Call. At this time, all participants are in a listen-only mode.

SALT LAKE CITY, Feb. 27, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics testing and precision medicine, today announced a collaboration with Gabbi ...